DALLAS, March 2, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring financial company Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI). The report includes financial, comparative and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The entire report is available at: http://www.beaconequity.com/i/SPPI
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Spectrum Pharmaceuticals Inc. (SPPI) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company's product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under collaboration with Allergan Inc. Another drug, ozarelix, is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH).
Message Board Search for SPPI: http://www.boardcentral.com/boards/SPPI
In the report, the analyst notes:
"Third quarter consolidated revenue of $7.1 million was comprised of product sales of $5.0 million -- $4.7 million from ZEVALIN and $0.3 million from FUSILEV(R) -- and $2.1 million attributable to the amortization of the Allergan licensing fee. This compares to no similar revenue in the same period in 2008. The Company recorded a net loss of $8.4 million, or 20 cents per share, compared to net loss of $8.8 million, or 28 cents per share, in the third quarter of 2008. Total research and development expenses were $5.5 million, as compared to $6.0 million in the same period of 2008, a $0.5 million, or 8.3% decrease, mainly due to sharing by its partner, Allergan Inc., of apaziquone related development costs, and a reduction in costs related to other pipeline products.
To read the entire report visit: http://www.beaconequity.com/i/SPPI
See what investors are saying about SPPI at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.